PCI SSC Sample Clauses

PCI SSC. Following Acceptance of a Product by PCI SSC, PCI SSC will communicate such Acceptance to the Assessor in accordance with the Program Documents, and post applicable details regarding the Product and Vendor on the Validated Product List. A Product is deemed to have been “Accepted” (and “Acceptance” is deemed to have occurred) when all of the following conditions have been met: (i) PCI SSC has received the corresponding Assessment Report regarding the Contracted Assessment of the Product from the Assessor in which the Assessor determines that the Product satisfies all applicable Program Requirements; (ii) PCI SSC has confirmed that the Assessment Report is correct as to form, that the Assessor adequately reported the compliance of the Product in accordance with applicable Program Requirements and that the detail provided in the Assessment Report meets Program Requirements; (iii) PCI SSC has received all applicable Program Fees and all other documentation required with respect to the Product; and (iv) PCI SSC has listed the Product on the Validated Product List (provided that PCI SSC may suspend, withdraw, revoke, cancel or place conditions upon (including without limitation, complying with remediation requirements) Acceptance of any Listed Product in accordance applicable with Program Requirements).
Sample 1
PCI SSC a. May amend, remove, add to or suspend any provision of any Program, cease to operate any Program, whether with or without replacing it with any other program, in its sole discretion, and without notice. b. Does not guarantee, warrant or endorse any Product. c. May, at its discretion, with respect to each Program, publish a list or lists of Products Accepted by PCI SSC thereunder, identifying the applicable validating Assessors and related Program participant information, together with corresponding Product status information (including without limitation, Acceptance, approval, suspension, remediation, and/or Revocation status) and other information identifying such Products, including without limitation, Vendor name and contact information, Product descriptions, version numbers, types, TPSs and TPSPs, target markets and reference numbers, information as to whether or not such Products and/or components thereof have satisfied applicable Program requirements, applicable Acceptance, validation, revalidation and expiry dates, reference, approval or acceptance numbers, deployment notes, PCI Standard version numbers, device types, hardware, firmware and application version numbers, and other information as identified or described in the Program Guide (the applicable list(s) for a given Program, the “Validated Product List”). d. May Revoke (i) a given Product in the event Vendor fails to timely pay applicable Program Fees for such Product or PCI SSC reasonably determines that Revocation of such Product is necessary as a result of (A) a Security Issue with respect to, or any defect, flaw, weakness or vulnerability in, such Product that compromises the security of such Product; (B) the failure of such Product to comply with requirements applicable to other Products of the same type; or
Sample 1
PCI SSC a. May amend, remove, add to or suspend any provision of any Program, and/or cease to operate any Program, whether with or without replacing it with any other program, in its sole discretion, and without notice. b. Does not guarantee, warrant or endorse any vendor or Product. c. May, at its discretion, with respect to each Program, publish a list or lists of Products and/or vendors (including Vendor, as applicable) Accepted by PCI SSC thereunder, identifying the applicable validating Assessors, related Program participant information, corresponding Product and/or vendor status information (including without limitation, Acceptance, approval, suspension, remediation, and/or Revocation status) and other information identifying such vendor or Products, including without limitation, vendor name and contact information, Product and/or software (as applicable) descriptions, version numbers, types, categories, and components thereof, TPPs and TPP Providers, target markets, locations, responsible business units, and reference numbers, information as to whether or not such Products, software and/or components thereof have satisfied applicable Program Requirements, applicable Acceptance, validation, revalidation and expiry dates, reference, approval or acceptance numbers, deployment notes, PCI Standard version numbers, device types, hardware, firmware and application version numbers, and other information as identified or described in the applicable Program Guide (the applicable list of Products and vendors Accepted by PCI SSC for a given Program, the “Validated List”; and the information and data provided as part of the Validated List for a given Product or vendor, the “Listing”). d. May Revoke (i) a given Listed Product in the event Vendor fails to timely pay applicable Program Fees for such Product or PCI SSC reasonably determines that Revocation of such Product is necessary as a result of (A) a Security Issue with respect to, or any other defect, flaw, weakness or vulnerability of such Product that compromises the security of such Product; (B) the failure of such Product to comply with requirements applicable to other Products of the same type or applicable Program Requirements; or (C) PCI SSC's determination that such Product is of a type that is not within the scope of the applicable Program or that Vendor’s rights to permit Acceptance of such Product are insufficient or in dispute (each of the circumstances described in preceding clause (i) a “Product Default”...
Sample 1

Related to PCI SSC

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Alcohol and Drug Testing Employee agrees to comply with and submit to any Company program or policy for testing for alcohol abuse or use of drugs and, in the absence of such a program or policy, to submit to such testing as may be required by Company and administered in accordance with applicable law and regulations.

  • XXXXXXXX ANTI-KICKBACK ACT (a) The Sub-Recipient hereby agrees that, unless exempt under Federal law, it will incorporate or cause to be incorporated into any contract for construction work, or modification thereof, the following clause: i. Contractor. The contractor shall comply with 18 U.S.C. § 874, 40 U.S.C. § 3145, and the requirements of 29 C.F.R. pt. 3 as may be applicable, which are incorporated by reference into this contract.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Course Curriculum, Instruction, and Grading X. Xxxx College courses offered as dual credit, regardless of where they are taught, follow the same syllabus, course outline, textbook, grading method, and other academic policies as the courses outlined in the Hill College catalog. B. Approved courses being taught for dual credit must follow the approved master syllabus of the discipline and of Hill College. C. Textbooks should be identical to those approved for use by Hill College. Should an instructor propose an alternative textbook, the textbook must be approved in advance by the appropriate instructional department of Hill College and the Vice President of Instruction. Other instructional materials for dual credit/concurrent courses must be identical or at an equivalent level to materials used by Hill College. D. Courses which result in college‐level credit will follow the standard grading practices of Hill College, as identified by college policy and as identified in the appropriately approved course syllabus. The grades used in college records are A (excellent), B (above average), C (average), D (below average), F (failure), I (incomplete), W (withdrawn), WC (withdrawn COVID). The lowest passing grade is D. Grade point averages are computed by assigning values to each grade as follows: A = 4 points, B = 3 points, C = 2 points, D = 1 point, and F = 0 points. Grading criteria may be devised by Hill College and the ISD to allow faculty the opportunity to award high school credit only or high school and college credit depending upon student performance. E. Faculty, who are responsible for teaching dual credit/concurrent classes, are responsible for keeping appropriate records, certifying census date rosters, providing interim grade reports, certifying final grade reports at the end of the semester, certifying attendance, and providing other reports and information as may be required by Hill College and/or the School District.

  • Medicaid Enrollment Treatment Grantees shall enroll as a provider with Texas Medicaid and Healthcare Partnership (TMHP) and all Medicaid Managed Care organizations in Grantee’s service region within the first quarter of this procurement term and maintain through the procurement term.

  • Prescription Drug Plan Retail and mail order prescription drug copays for bargaining unit employees shall be as follows:

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Medi Cal/daily service logs and notes and other documents used to record provision of services provided by instructional assistants, behavior intervention aides, bus aides, and supervisors

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!